479422-24-7

Upstream product

• 99-76-3 methyl 4-hydroxylbenzoate 
• 776-74-9 Bromodiphenylmethane 
• 93749-47-4 methyl 4-(2,2-diethoxyethoxy)benzoate 
• 124064-21-7 4-(2-oxo-ethoxy)-benzoic acid methyl ester 
• 479422-23-6 methyl 4-[2-(5-chloro-2-methyl-1H-indol-3-yl)ethoxy]benzoate 

Downstream Products

• 479422-22-5 NCG⁽²⁵⁰⁾C₀₀₃₈₉-01 
• 683813-75-4 C₃₂H₂₆Br₂ClNO₃ 
• 479422-27-0 4-{2-[1-benzhydryl-5-chloro-2-(hydroxymethyl)-1H-indol-3-yl]ethoxy}benzoic acid 
• 1026928-66-4 C₃₃H₃₀ClNO₆S 
• 934284-70-5 methyl 4-{2-[2-(azidomethyl)-5-chloro-1-(diphenylmethyl)-1H-indol-3-yl]ethoxy}benzoate 
• 934284-72-7 methyl 4-{2-[2-(aminomethyl)-1-benzhydryl-5-chloro-1H-indol-3-yl]ethoxy}benzoate 
• 934284-76-1 methyl 4-{2-[1-benzhydryl-2-({[(benzyloxy)carbonyl]amino}methyl)-5-chloro-1H-indol-3-yl]ethoxy}benzoate 
• 934286-16-5 methyl 4-{2-[5-chloro-2-(2-{[(2-chlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]ethoxy}benzoate 
• 683812-99-9 methyl 4-{2-[5-chloro-2-(2-{[(4-chlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]ethoxy}benzoate 
• 683813-12-9 methyl 4-{2-[5-chloro-2-(2-{[(2,3-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]ethoxy}benzoate 
• 683813-13-0 methyl 4-{2-[5-chloro-2-(2-{[(2,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]ethoxy}benzoate 
• 683812-95-5 methyl 4-{2-[5-chloro-2-(2-{[(3,5-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]ethoxy}benzoate 
• 683812-94-4 methyl 4-{2-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]ethoxy}benzoate 
• 934284-80-7 methyl 4-[2-(1-benzhydryl-2-{[(benzylsulfonyl)amino]methyl}-5-chloro-1H-indol-3-yl)ethoxy]benzoate 

Relevant academic research and scientific papers

Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis

This invention provides methods for the use of substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof. The invention provides methods for the use of the compounds in the treating or preventing thrombosis in a mammal, or preventing progression of symptoms of thrombosis.

An efficient synthesis of Ecopladib

An efficient synthesis of Ecopladib, an indole inhibitor of cytosolic phospholipase A2α, is described. A new reaction involving indole C3 reductive alkylation using an acetal in the absence of water and a novel transformation of the C2 methyl t

INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2

This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLAα). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.

Inhibition of cytosolic phospholipase A2α: Hit to lead optimization

Compound 1 was previously reported to be a potent inhibitor of cPLA 2α in both artificial monomeric substrate and cell-based assays. However, 1 was inactive in whole blood assays previously used to characterize cyclooxygenase and lipoxygenase inhibitors. The IC50 of 1 increased dramatically with cell number or lipid/detergent concentration. In an attempt to insert an electrophilic ketone between the indole and benzole acid moieties, we discovered that increasing the distance between the two moieties gave a compound with activity in the GLU (7-hydroxycoumarinyl-γ- linolenate) micelle assay, which contains lipid and detergent. Extensive structure-activity relationship work around this lead identified a potent pharmacophore for cPLA2α inhibition. The IC50s between the GLU micelle and rat whole blood assays correlated highly. No correlation was found for other parameters, including lipophilicity or acidity of the required acid functionality. Compounds 25, 39, and 94 emerged as potent, selective inhibitors of cPLA2α and represent well-validated starting points for further optimization.

Process for making an aldehyde

A process for making an aromatic aldehyde in which a sulfoxide is reacted with a dihalogenated aromatic compound in the absence of an effective amount of an activating reagent. The aldehyde may then be used to make other compounds, such as a compound that acts as a cPLA inhibitor.